Target Price | NOK19.38 |
Price | NOK11.06 |
Potential |
75.23%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Elliptic Laboratories 2026 .
The average Elliptic Laboratories target price is NOK19.38.
This is
75.23%
register free of charge
NOK19.95
80.38%
register free of charge
NOK19.19
73.51%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend Elliptic Laboratories to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Elliptic Laboratories stock has an average upside potential 2026 of
75.23%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million NOK | 131.91 | 224.64 |
93.08% | 70.30% | |
EBITDA Margin | 19.82% | 55.94% |
142.44% | 182.18% | |
Net Margin | 6.79% | 33.79% |
112.18% | 397.46% |
5 Analysts have issued a sales forecast Elliptic Laboratories 2025 . The average Elliptic Laboratories sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Elliptic Laboratories EBITDA forecast 2025. The average Elliptic Laboratories EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Elliptic Laboratories Analysts have issued a net profit forecast 2025. The average Elliptic Laboratories net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share NOK | 0.08 | 0.72 |
121.62% | 800.00% | |
P/E | 15.76 | |
EV/Sales | 5.32 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.